Celgene's Otezla nabs psoriasis approval, launching next-gen showdown

Celgene's ($CELG) anti-inflammatory newcomer Otezla just took another step toward the powerhouse. The drug won FDA approval in a big market important to its sales: psoriasis, the most common autoimmune disease in the U.S. It's the first in a new generation of psoriasis meds to nab that indication.

And therein lies the challenge for the drug--and the others soon to hit the market. Already up against a raft of tried-and-true treatments, Otezla will soon contend with a crowd of newcomers. Eli Lilly ($LLY), Novartis ($NVS), Amgen ($AMGN), AstraZeneca ($AZN), Merck ($MRK), Johnson & Johnson ($JNJ)--all of them have psoriasis hopefuls, and most have plenty of experience in the anti-inflammatory market.

Other threats? Older psoriasis treatments Humira, Enbrel and Remicade are well entrenched; in fact, they're the three top-selling drugs in the world. Then there are Enbrel biosimilars, targeted by Novartis' generics unit Sandoz and India's Cipla, among others. Remicade biosimilars, too. Johnson & Johnson's ($JNJ) Stelara, one of the market's more recent brand-name entries, has legs already; it's expected to hit $1.4 billion in sales by 2015, according to DataMonitor.

Still, Otezla (apremilast) is expected to hit blockbuster territory by 2018, with $1.3 billion in sales by then. It's a pill, versus an injection, which will help. And Celgene is working on other indications for Otezla, including rheumatoid arthritis, potentially a big one.

- read the Celgene release

Special Reports: Top 10 best-selling drugs of 2013 - Humira - Enbrel - Remicade

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.